RELATIVE CONTRIBUTIONS OF THE FIVE MAJOR HUMAN CYTOCHROMES P450, 1A2, 2C9, 2C19, 2D6, AND 3A4, TO THE HEPATIC METABOLISM OF THE PROTEASOME INHIBITOR BORTEZOMIB

The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.

Teru Hideshima, Paul G. Richardson, D Chauhan et al. · PubMed · 2001 · 1.5K citations

Medicine, Oncology, Pharmacology +17

The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans.

S.M. de Morais, G. Wilkinson, Joyce Blaisdell et al. · Journal of Biological Chemistry · 1994 · 952 citations · Full text

Medicine, Genetics, Pharmacology +17

Potent and selective inhibitors of the proteasome: Dipeptidyl boronic acids

Julian Adams, Mark L. Behnke, Shaowu Chen et al. · Bioorganic & Medicinal Chemistry Letters · 1998 · 683 citations · Full text

Life Sciences, Biochemistry, Medicinal Chemistry +12

COMPARISON OF INHIBITORY EFFECTS OF THE PROTON PUMP-INHIBITING DRUGS OMEPRAZOLE, ESOMEPRAZOLE, LANSOPRAZOLE, PANTOPRAZOLE, AND RABEPRAZOLE ON HUMAN CYTOCHROME P450 ACTIVITIES

Xueqing Li, Tommy B. Andersson, Marie M. Ahlström et al. · Drug Metabolism and Disposition · 2004 · 642 citations

Medicine, Pharmacokinetics, Pharmacology +17

Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes.

Deborah J. Newton, R W Wang, Anthony Y.H. Lu · Drug Metabolism and Disposition · 1995 · 606 citations

Medicine, Pharmacokinetics, Pharmacology +17